Our methods are reviewed in the open literature and engaged with the regulators that matter. Below: the foundation we've built since 2019.
Peer-reviewed publication demonstrating NetraAI's ability to identify clinically interpretable subgroups in small, high-dimensional trial datasets.
Published five-component Regulatory Defensibility Index designed for the FDA's emerging AI-native review environment.
Plenary presentation at the American Society of Clinical Psychopharmacology annual meeting.
Spanning psychiatry, oncology, and CNS — co-authored with collaborators at leading academic centers.